These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 16798643

  • 1. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ.
    Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
    [Abstract] [Full Text] [Related]

  • 2. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ.
    Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
    [Abstract] [Full Text] [Related]

  • 3. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 4. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ, Kolnagou A.
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [Abstract] [Full Text] [Related]

  • 5. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 Jun; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Jun; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
    Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB.
    Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
    [Abstract] [Full Text] [Related]

  • 8. Pathogenesis and management of iron toxicity in thalassemia.
    Hershko C.
    Ann N Y Acad Sci; 2010 Aug; 1202():1-9. PubMed ID: 20712765
    [Abstract] [Full Text] [Related]

  • 9. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Aug; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 10. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 Aug; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 11. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
    Kontoghiorghes GJ, Efstathiou A, Kleanthous M, Michaelides Y, Kolnagou A.
    Hemoglobin; 2009 Aug; 33(5):386-97. PubMed ID: 19814684
    [Abstract] [Full Text] [Related]

  • 12. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT, Tsai CH, Wu KH.
    Hemoglobin; 2008 Aug; 32(1-2):49-62. PubMed ID: 18274983
    [Abstract] [Full Text] [Related]

  • 13. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ.
    Hemoglobin; 2008 Aug; 32(1-2):17-28. PubMed ID: 18274979
    [Abstract] [Full Text] [Related]

  • 14. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y, Evans P, Manz CY, Porter JB.
    Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
    [Abstract] [Full Text] [Related]

  • 15. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
    Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C.
    J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
    [Abstract] [Full Text] [Related]

  • 16. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ.
    Hemoglobin; 2008 Aug; 32(1-2):1-15. PubMed ID: 18274978
    [Abstract] [Full Text] [Related]

  • 17. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
    Kontoghiorghes GJ, Kolnagou A, Skiada A, Petrikkos G.
    Hemoglobin; 2010 Jun; 34(3):227-39. PubMed ID: 20524813
    [Abstract] [Full Text] [Related]

  • 18. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
    Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A.
    Curr Med Chem; 2005 Jun; 12(23):2663-81. PubMed ID: 16305464
    [Abstract] [Full Text] [Related]

  • 19. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A, Fink D, Admoni O, Tennenbaum-Rakover Y, Levin C.
    Eur J Haematol; 2010 Jan 01; 84(1):72-8. PubMed ID: 19732137
    [Abstract] [Full Text] [Related]

  • 20. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.
    Haematologica; 2003 Dec 01; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.